Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control.
U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807), was tested against 4,742 fresh clinical isolates from four large medical centers. U-76,253A was very active against nearly all species of Enterobacteriaceae (87.7% inhibited at less than or equal to 4.0 micrograms/ml). Staphylococcus spp., and the streptococci. The U-76,253A spectrum was superior to the comparison orally administered cephalosporins (cephalexin, cephradine, cefaclor). Pseudomonas spp., Acinetobacter spp., and the enterococci were resistant to U-76,253A and the other tested drugs. Broth microdilution MIC quality control (QC) limits were established for U-76,253A in a multilaboratory investigation using a minimum of 125 MIC determinations per organism. The following MIC QC ranges were recommended; Escherichia coli (ATCC 25922) = 0.25-1.0 micrograms/ml, Staphylococcus aureus (ATCC 29213) = 2.0-4.0 micrograms/ml and Pseudomonas aeruginosa (ATCC 27853) = greater than 32 micrograms/ml.
Jones
R N
RN
Clinical Microbiology Institute, Tualatin, OR 97062.
Barry
A L
AL
Pfaller
M
M
Allen
S D
SD
Ayers
L W
LW
Fuchs
P C
PC
D000284:Administration, Oral; D002433:Cefaclor / Q000494:pharmacology; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002506:Cephalexin / Q000494:pharmacology; D002511:Cephalosporins / Q000008:administration & dosage / Q000494:pharmacology* / Q000592:standards; D002515:Cephradine / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D011786:Quality Control; D000097623:Cefpodoxime; D000097627:Cefpodoxime Proxetil
D002433:Cefaclor; D015296:Ceftizoxime; D002506:Cephalexin; D002511:Cephalosporins; D002515:Cephradine; D000097623:Cefpodoxime; D000097627:Cefpodoxime Proxetil